Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...
Evaluate VP of Thought Leadership Daniel Chancellor discusses trends for 2025 as the surge in R&D, coupled with rapidly ...
The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...
The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...
Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in ...
Three-dimensional (3D) printing is a 20-year-old technology whose time finally seems to have arrived. Interest in the equipment rose sharply last year; in 2012, the market for 3D products reached $777 ...
Life Science Leader is an essential business publication for life science executives who work at everything from emerging biotechs to large pharmaceutical companies. Our content is designed to inform ...
The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering ...
Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...
Many studies are evaluating natural killer (NK) cells as potential cancer treatments. However, it is challenging to obtain primary human NK cells at clinically relevant scale. Here, we generated 1 × ...
Kevin Wall is principal consultant and owner of Cincero Consulting. He has worked with five virtual pharmaceutical companies to move eight of their drug substance and drug product projects through ...